BioCryst Pharmaceuticals’ (BCRX) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research report report published on Tuesday morning,Benzinga reports. Needham & Company LLC currently has a $14.00 target price on the biotechnology company’s stock.

Other research analysts also recently issued research reports about the stock. StockNews.com upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 6th. Barclays raised their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. Finally, JMP Securities upped their target price on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 6th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.67.

BioCryst Pharmaceuticals Trading Down 0.8 %

Shares of BCRX stock opened at $7.67 on Tuesday. BioCryst Pharmaceuticals has a 12-month low of $4.03 and a 12-month high of $8.88. The business’s 50 day moving average is $7.78 and its two-hundred day moving average is $6.98. The company has a market capitalization of $1.59 billion, a P/E ratio of -12.57 and a beta of 1.89.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.07). The company had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. BioCryst Pharmaceuticals’s revenue was up 35.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.19) EPS. On average, research analysts predict that BioCryst Pharmaceuticals will post -0.37 earnings per share for the current fiscal year.

Institutional Trading of BioCryst Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. CWM LLC boosted its position in shares of BioCryst Pharmaceuticals by 200.0% during the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 3,772 shares during the last quarter. Signaturefd LLC boosted its holdings in BioCryst Pharmaceuticals by 560.5% in the 2nd quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 5,599 shares during the last quarter. Seven Eight Capital LP acquired a new position in BioCryst Pharmaceuticals in the 1st quarter valued at about $57,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of BioCryst Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 1,322 shares during the period. Finally, Natixis increased its holdings in shares of BioCryst Pharmaceuticals by 400.6% during the 1st quarter. Natixis now owns 11,684 shares of the biotechnology company’s stock worth $59,000 after buying an additional 9,350 shares during the last quarter. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.